Crossmark Global Holdings Inc. Has $1.63 Million Stock Position in Illumina, Inc. $ILMN

Crossmark Global Holdings Inc. grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 52.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,461 shares of the life sciences company’s stock after purchasing an additional 4,278 shares during the period. Crossmark Global Holdings Inc.’s holdings in Illumina were worth $1,634,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Creative Capital Management Investments LLC increased its holdings in shares of Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. Board of the Pension Protection Fund bought a new stake in shares of Illumina during the fourth quarter valued at approximately $26,000. TD Waterhouse Canada Inc. bought a new stake in shares of Illumina during the fourth quarter valued at approximately $26,000. Laurel Wealth Advisors LLC bought a new stake in shares of Illumina during the fourth quarter valued at approximately $26,000. Finally, Activest Wealth Management increased its holdings in shares of Illumina by 671.9% during the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 215 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 2.2%

Illumina stock opened at $145.70 on Wednesday. Illumina, Inc. has a fifty-two week low of $77.50 and a fifty-two week high of $155.53. The stock has a market cap of $22.04 billion, a PE ratio of 26.49, a price-to-earnings-growth ratio of 2.36 and a beta of 1.42. The firm’s 50-day simple moving average is $127.79 and its 200 day simple moving average is $128.81. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the company earned $0.97 earnings per share. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts predict that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of analyst reports. Robert W. Baird set a $137.00 price objective on shares of Illumina in a report on Friday, February 6th. Piper Sandler dropped their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Guggenheim raised their target price on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. Weiss Ratings lowered Illumina from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Finally, Canaccord Genuity Group dropped their target price on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a report on Friday, May 1st. Six analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $131.06.

Insider Activity at Illumina

In other news, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the transaction, the senior vice president directly owned 15,056 shares of the company’s stock, valued at $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.